Nadine F Choueiter1, Aaron K Olson, Danny D Shen, Michael A Portman. 1. Division of Cardiology, Department of Pediatrics, University of Washington and Center for Developmental Therapeutics, Seattle Children's Hospital and Research Institute, Seattle, WA, USA.
Abstract
OBJECTIVE: To determine the safety and pharmacokinetics of etanercept (Amgen, Thousand Oaks, California) a tumor necrosis factor-α receptor blocker, in children with acute Kawasaki disease (KD). Standard therapy of acute KD includes intravenous immunoglobulin (IVIG) and high-dose aspirin, but a substantial number of patients are refractory and require additional treatment. Tumor necrosis factor-α levels are elevated in children with KD, suggesting a role for etanercept in treatment. STUDY DESIGN: We performed a prospective open-label trial of etanercept in patients with KD (age range, 6 months-5 years; n = 17) meeting clinical criteria and with fever ≤ 10 days. All received IVIG and high-dose aspirin. They received etanercept immediately after IVIG infusion and then weekly two times. For the initial safety evaluation, the first 5 patients received 0.4 mg/kg/dose. Subsequent subjects received 0.8 mg/kg/dose. RESULTS: Fifteen patients completed the study. The pharmacokinetics were similar to that in older children in published series. No serious adverse events related to etanercept occurred. No patient demonstrated prolonged or recrudescent fever requiring re-treatment with IVIG. No patient showed an increase in coronary artery diameter or new coronary artery dilation/cardiac dysfunction. CONCLUSION: Etanercept appears to be safe and well tolerated in children with KD. The data support performance of a placebo-controlled trial.
OBJECTIVE: To determine the safety and pharmacokinetics of etanercept (Amgen, Thousand Oaks, California) a tumor necrosis factor-α receptor blocker, in children with acute Kawasaki disease (KD). Standard therapy of acute KD includes intravenous immunoglobulin (IVIG) and high-dose aspirin, but a substantial number of patients are refractory and require additional treatment. Tumor necrosis factor-α levels are elevated in children with KD, suggesting a role for etanercept in treatment. STUDY DESIGN: We performed a prospective open-label trial of etanercept in patients with KD (age range, 6 months-5 years; n = 17) meeting clinical criteria and with fever ≤ 10 days. All received IVIG and high-dose aspirin. They received etanercept immediately after IVIG infusion and then weekly two times. For the initial safety evaluation, the first 5 patients received 0.4 mg/kg/dose. Subsequent subjects received 0.8 mg/kg/dose. RESULTS: Fifteen patients completed the study. The pharmacokinetics were similar to that in older children in published series. No serious adverse events related to etanercept occurred. No patient demonstrated prolonged or recrudescent fever requiring re-treatment with IVIG. No patient showed an increase in coronary artery diameter or new coronary artery dilation/cardiac dysfunction. CONCLUSION: Etanercept appears to be safe and well tolerated in children with KD. The data support performance of a placebo-controlled trial.
Authors: B Bozkurt; G Torre-Amione; M S Warren; J Whitmore; O Z Soran; A M Feldman; D L Mann Journal: Circulation Date: 2001-02-27 Impact factor: 29.690
Authors: D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck Journal: N Engl J Med Date: 2000-03-16 Impact factor: 91.245
Authors: H Kato; T Sugimura; T Akagi; N Sato; K Hashino; Y Maeno; T Kazue; G Eto; R Yamakawa Journal: Circulation Date: 1996-09-15 Impact factor: 29.690
Authors: Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson Journal: Circulation Date: 2003-06-09 Impact factor: 29.690
Authors: Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman Journal: Pediatrics Date: 2019-05-02 Impact factor: 7.124
Authors: Ludovico Iannetti; Roberta Zito; Simone Bruschi; Laura Papetti; Fiorenza Ulgiati; Francesco Nicita; Francesca Del Balzo; Alberto Spalice Journal: Clin Dev Immunol Date: 2012-09-12